The experimental system focused on the widely studied JAK2V617F mutation. JAK2 is an enzyme that normally transmits signals from cytokine receptors to the cell nucleus, helping regulate blood-cell production. The V617F mutation changes a single DNA base, producing a permanently active version of the enzyme. Instead of responding only when instructed by external growth signals, mutant JAK2 can continuously stimulate pathways that promote cell survival and proliferation. The mutation is found in many cases of polycythemia vera and in a substantial fraction of essential thrombocythemia and myelofibrosis, disorders in which excessive blood-cell production and persistent inflammation can contribute to clotting, bone-marrow scarring and disease progression.

The researchers explored whether spherical gold nanoparticles could be used to interfere with this abnormal biology while also altering the cells’ response to genetic material. Each particle was about 13 nanometres across before it was coated with strands of DNA-like oligonucleotides, producing a final construct roughly 25 nanometres in diameter. The attached sequences were designed to pair with messenger RNA encoding either normal JAK2 or the JAK2V617F mutant. Pairing an oligonucleotide with its complementary messenger RNA can destabilize the transcript or hinder its translation, potentially reducing production of the corresponding protein. Gold nanoparticles are useful carriers because dense layers of nucleic acids on their surfaces can improve stability and promote uptake through endocytosis, the process by which cells engulf material into membrane-bound compartments.

The team treated three human cell lines with the constructs at a concentration of 200 picomolar and measured their responses over intervals ranging from 30 minutes to 72 hours. HEL cells carry two copies of JAK2V617F and resemble aspects of polycythemia vera. SET2 cells carry one mutant copy and are used as a model related to essential thrombocythemia. K562 cells, included as a comparison, lack JAK2V617F and instead carry the BCR-ABL fusion associated with chronic myeloid leukemia. The researchers also used nanoparticles bearing scrambled oligonucleotide sequences that were not designed to match any cellular transcript. Gene activity was assessed using quantitative reverse-transcription PCR, while receptor proteins were examined by flow cytometry and secreted inflammatory molecules were measured in the culture medium.

The most dramatic pattern emerged in pathways that detect nucleic acids, the molecular material of DNA and RNA. TLR9 is an intracellular receptor that recognizes DNA containing particular CpG motifs and can activate inflammatory transcription programs. One of its downstream regulators is IRF7, a transcription factor that helps drive type I interferon responses, while NF-κB, represented in the study by the NFKB1 gene, controls a broad range of inflammatory and survival-related genes. Following nanoparticle exposure, these systems showed little change during the first few hours, but their activity shifted later. TLR9 expression rose sharply in SET2 cells after 24 and 48 hours, reaching approximately 200- to 300-fold above control levels before falling toward baseline by 72 hours. The response did not clearly depend on whether the attached sequence targeted normal JAK2, mutant JAK2 or neither.

IRF7 displayed an even stronger mutation-associated response. In HEL cells, nanoparticles directed against JAK2V617F produced an approximately 20-fold increase in IRF7 expression at later time points. In SET2 cells, the increase approached 100-fold. These effects were much more pronounced than in the JAK2V617F-negative K562 line, suggesting that the mutant signaling environment altered how cells processed or responded to the nanoparticle-bound oligonucleotides. NFKB1 also increased after longer exposure, particularly in HEL and SET2 cells, where JAK2- and JAK2V617F-targeting particles produced roughly tenfold increases at 24 or 48 hours. K562 cells responded later and less consistently, reinforcing the idea that the nanoparticles were not acting through a single universal mechanism.

The second major surveillance system, known as cGAS-STING, responded in a similarly complicated fashion. cGAS detects DNA that appears in the cell’s cytoplasm, where it normally should not be. Once activated, it produces the small messenger molecule cyclic GMP-AMP, which binds to STING on the endoplasmic reticulum. STING then recruits the kinase TBK1, leading to activation of IRF3 and production of interferons and other inflammatory signals. In the experiments, cGAS expression generally increased after prolonged nanoparticle treatment, including in all three cell lines under at least some conditions. Yet STING did not rise in parallel. In K562 cells, for example, cGAS was strongly induced while STING showed little obvious response. This mismatch suggests that increasing the amount of cGAS does not necessarily activate the entire pathway; protein modification, degradation, trafficking or epigenetic repression may determine whether STING can transmit the signal.

The researchers also investigated RAGE, a receptor that can assist the delivery of extracellular nucleic acids into endosomes, the compartments where TLR9 is located. If the nanoparticles were activating TLR9 through a RAGE-dependent route, changes in RAGE protein might have been expected. Instead, flow-cytometry measurements in HEL cells found no significant changes in either surface or intracellular RAGE after short or long exposure to JAK2- or JAK2V617F-targeting particles. Intracellular TLR9 protein levels also remained largely unchanged, even when TLR9 messenger RNA increased. This distinction between RNA and protein is biologically important. Gene expression measured by PCR indicates that a transcript is more abundant, but it does not guarantee that more receptor will be produced. Messenger RNAs can be stabilized, trapped by RNA-binding proteins, transported differently or prevented from being efficiently translated. The result suggests that the delayed inflammatory response may be controlled downstream of transcription or through a pathway that does not require RAGE.

Cytokine measurements supplied a functional readout of the molecular changes. The investigators tested a broad panel that included interferons, tumour-necrosis factor, interleukins and the chemokine MCP-1, but IL-8, also called CXCL8, was the most notable signal. IL-8 levels increased in media from the JAK2V617F-positive HEL and SET2 cultures after extended treatment, with HEL cells showing a particularly strong response and a peak reported around 48 hours for some nanoparticle conditions. IL-8 attracts and activates immune cells and has been associated in myeloproliferative neoplasms with leukocytosis, thrombosis and bone-marrow fibrosis. Its induction therefore underscores both the therapeutic promise and the potential hazard of the approach: a particle intended to dampen pathological inflammation could, after a delay, stimulate inflammatory outputs depending on dose, sequence and cellular context.

The authors describe this behaviour as a biphasic response. In the short term, oligonucleotide-coated gold nanoparticles can suppress components of TLR9, IRF7 and related signaling networks, potentially reducing inflammatory activity. Over the following day or two, however, the same treatment can provoke increased expression of IRF7, TLR9, cGAS or NF-κB-associated genes, especially in cells carrying JAK2V617F. Such timing could reflect nanoparticle trafficking through endosomes, gradual release or processing of the attached oligonucleotides, delayed feedback from interferon signaling, or compensatory responses to attempted JAK2 suppression. The investigators emphasize that the effects were not always sequence-specific: scrambled nanoparticles sometimes produced comparable changes, raising the possibility that the gold core, the nucleic-acid coating or cellular uptake itself contributes to the response.

That complexity means the study is better viewed as a molecular map than as evidence of a ready-to-use treatment. The experiments used only three established cell lines, each with distinct origins and signaling abnormalities, and relied on a small number of replicate wells and PCR runs. The work did not demonstrate that the nanoparticles reduced cell proliferation, eliminated mutant clones or improved disease features in an organism. It also did not establish how the particles would distribute through the body, whether they would accumulate in the liver or spleen, how long they would persist, or whether they would trigger unwanted immune reactions. Before clinical testing, researchers will need to identify the precise mechanisms behind the early suppression and delayed activation, define safe exposure windows, test primary patient cells and evaluate toxicity in animal models.

Even so, the results highlight an emerging strategy in precision medicine: targeting not only an oncogenic mutation but also the inflammatory circuitry that sustains blood cancer. Because JAK2V617F-positive cells showed distinct IRF7 responses from mutation-negative cells, future nanoparticle designs might be tailored to particular genetic and disease subtypes. They could potentially be combined with existing JAK inhibitors, which block aberrant signaling but do not always eliminate the malignant clone or fully control inflammation. The immediate challenge is to turn the nanoparticles’ unpredictable timing into a controllable feature. If researchers can preserve the initial dampening effect while preventing the later inflammatory rebound, gold-bound oligonucleotides may become a versatile platform for modulating nucleic-acid sensing in myeloproliferative neoplasms and other inflammation-driven cancers.

Subject of Research: Oligonucleotide-coated gold nanoparticles and their effects on nucleic-acid sensing, inflammatory signaling and cytokine production in JAK2V617F-positive myeloproliferative neoplasm cell models

Article Title: Suppressed activation of the IRF7 and TLR9 by JAK2V617F gold nanoparticles

Article References: Tokcan, B., Demirtaş, E.N. & Sözer, S. “Suppressed activation of the IRF7 and TLR9 by JAK2V617F gold nanoparticles.” Immunogenetics 77, 16 (2025). Original research article

Image Credits: AI Generated

DOI: 10.1007/s00251-025-01374-y

Keywords: JAK2V617F, gold nanoparticles, oligonucleotide delivery, TLR9, IRF7, cGAS-STING, IL-8, myeloproliferative neoplasms

Myeloproliferative neoplasms are a group of clonal blood diseases characterized by the excessive production of mature myeloid cells, often leading to complications including thrombosis, bone marrow fibrosis, and transformation to acute leukemia. The JAK2V617F mutation is a well-established oncogenic driver found in the majority of MPN patients, but how this genetic lesion cooperates with the host’s inflammatory milieu to influence disease evolution has remained elusive until now.

The study conducted by Koerber et al., published in Nature Communications, delves deeply into the molecular crosstalk between mutated hematopoietic cells and systemic inflammation orchestrated by the NLRP3 inflammasome, a cytosolic multiprotein complex known for its central role in innate immunity and production of pro-inflammatory cytokines such as IL-1β and IL-18. By employing genetically engineered mouse models combined with patient-derived samples, the research team meticulously dissected the impact of NLRP3 activation on disease burden and progression.

Remarkably, their findings indicate that the presence of the JAK2V617F mutation alone is insufficient to recapitulate the full spectrum of MPN pathology unless accompanied by robust systemic inflammation mediated by NLRP3. In mice genetically deficient in Nlrp3, the hallmark features of MPN such as splenomegaly, aberrant myelopoiesis, and fibrotic transformation were significantly attenuated. This suggests a model in which the inflammasome acts as a critical amplifier of oncogenic JAK2 signaling, tipping the balance towards malignant expansion and pathological remodeling of the bone marrow microenvironment.

Delving into the mechanistic layers, the researchers uncovered that NLRP3 activation leads to caspase-1-dependent processing of inflammatory cytokines, which in turn sustain a pro-inflammatory niche. This environment facilitates the expansion and survival of JAK2V617F mutant clones, potentially by promoting signaling pathways that prevent apoptosis and augment proliferation. Intriguingly, the study also observed increased pyroptotic cell death in non-mutant hematopoietic cells, likely contributing to selective advantage of mutant clones by reducing competition.

One of the most compelling aspects of this research is the therapeutic implication that targeting the NLRP3 inflammasome could serve as a novel strategy to modulate the course of MPNs. The authors tested pharmacologic inhibitors of NLRP3 in their murine models and found a marked reduction in disease phenotypes, including normalization of blood counts and reduction in splenic and marrow fibrosis. These results underscore the inflammasome not just as a biomarker of disease activity, but as a viable molecular target.

Moreover, the study revealed that the NLRP3 inflammasome contributes to systemic symptoms observed in MPN patients, such as fatigue, fever, and weight loss, collectively known as “constitutional symptoms.” By controlling systemic levels of IL-1β and IL-18, NLRP3 activation may be driving chronic inflammation that extends beyond the bone marrow, affecting multiple physiological systems. This insight opens the possibility that inflammasome inhibition could ameliorate both hematologic abnormalities and debilitating symptomatic burdens simultaneously.

Investigations into human patient samples corroborated the murine data, with elevated expression of NLRP3 pathway components detected in peripheral blood cells of JAK2V617F-positive MPN patients compared to healthy controls. Correlation analyses further linked inflammasome activation levels with disease severity and symptom scores, lending clinical relevance to the experimental findings.

The study’s authors emphasize that this paradigm shift redefines inflammation in MPN from a mere epiphenomenon to a central pathogenic driver. By linking mutational events with innate immune pathways, the research bridges oncology and immunology, highlighting the complexity of tumor-host interactions. Such insights can revolutionize how clinicians approach MPN treatment, potentially combining targeted kinase inhibitors with anti-inflammatory agents for synergistic effects.

This integrative perspective also provokes questions about the role of environmental and lifestyle factors that influence systemic inflammation in MPN risk and progression. Could chronic low-grade inflammation from infections, metabolic dysregulation, or other comorbidities prime the inflammasome, thereby accelerating disease emergence or relapse? Such considerations extend the implications of the work beyond molecular biology into personalized medicine and disease prevention.

While the precise triggers initiating NLRP3 activation in the context of JAK2-mutant hematopoiesis remain to be fully elucidated, the study hints at roles for oxidative stress, mitochondrial dysfunction, and danger-associated molecular patterns (DAMPs) released in the tumor microenvironment. Further dissection of these upstream signals promises to not only advance fundamental understanding but also identify additional drug targets.

As the scientific community digests these compelling findings, future research will likely explore inflammasome-targeted therapies in clinical trials, assessing efficacy, safety, and impact on quality of life. Given the chronic and often progressive nature of MPNs, strategies that can sustainably modulate inflammatory circuits without compromising host defense will be paramount.

This breakthrough underscores the importance of cross-disciplinary research that integrates immunology, genetics, and hematology to unravel the complexities of cancer biology. The paradigm emerging from Koerber et al.’s work positions the NLRP3 inflammasome as a master regulator connecting oncogenic mutation to microenvironmental inflammation, a nexus with profound therapeutic potential.

In conclusion, by uncovering the indispensable role of NLRP3-induced systemic inflammation in governing the fate of JAK2V617F mutant myeloproliferative neoplasms, this study not only advances our understanding of MPN pathophysiology but also paves the way for innovative treatment paradigms aiming to transform patient outcomes. As we venture further into precision medicine, targeting inflammation may prove as crucial as targeting oncogenic drivers themselves.

Subject of Research: The role of NLRP3 inflammasome-driven systemic inflammation in regulating the development and progression of JAK2V617F mutant myeloproliferative neoplasms.

Article Title: NLRP3-induced systemic inflammation controls the development of JAK2V617F mutant myeloproliferative neoplasms.

Article References:
Koerber, RM., Krollmann, C., Cieslak, K. et al. NLRP3-induced systemic inflammation controls the development of JAK2V617F mutant myeloproliferative neoplasms. Nat Commun 16, 10591 (2025). https://doi.org/10.1038/s41467-025-65673-4

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41467-025-65673-4